Sage Therapeutics, Inc. (SAGE) Is At $172.86 Formed Wedge; MX GOLD ORDINARY SHARES (MXLGF) Shorts Raised By 31.48%

Sage Therapeutics, Inc. (NASDAQ:SAGE) Logo

MX GOLD CORP ORDINARY SHARES (OTCMKTS:MXLGF) had an increase of 31.48% in short interest. MXLGF’s SI was 14,200 shares in May as released by FINRA. Its up 31.48% from 10,800 shares previously. The SI to MX GOLD CORP ORDINARY SHARES’s float is 0.01%. The stock decreased 0.18% or $6E05 during the last trading session, reaching $0.03394. About shares traded. MX Gold Corp. (OTCMKTS:MXLGF) has 0.00% since May 15, 2017 and is . It has underperformed by 11.55% the S&P500.

Sage Therapeutics, Inc. (SAGE) formed wedge down with $157.30 target or 9.00% below today’s $172.86 share price. Sage Therapeutics, Inc. (SAGE) has $8.04B valuation. The stock increased 1.31% or $2.24 during the last trading session, reaching $172.86. About 396,159 shares traded. Sage Therapeutics, Inc. (NASDAQ:SAGE) has risen 135.95% since May 15, 2017 and is uptrending. It has outperformed by 124.40% the S&P500.

MX Gold Corp., a natural resource company, engages in the acquisition, exploration, and development of mining properties in Canada. The company has market cap of $24.39 million. The firm explores for gold, copper, and silver deposits. It currently has negative earnings. It primarily holds a 100% interest in the Willa property with 21 mineral claims covering a surface area of approximately 5,329 hectares located in the Slocan mining division, British Columbia.

Since December 14, 2017, it had 0 insider buys, and 6 selling transactions for $42.42 million activity. $9.57 million worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) was sold by Robichaud Albert on Thursday, December 14. Shares for $9.96 million were sold by STARR KEVIN P on Tuesday, April 17. Kanes Stephen had sold 44,000 shares worth $7.80 million. The insider FRATES JAMES M sold 7,000 shares worth $1.08 million. The insider PAUL STEVEN M sold $10.00M. On Monday, April 23 IGUCHI KIMI sold $4.02M worth of Sage Therapeutics, Inc. (NASDAQ:SAGE) or 28,153 shares.

Analysts await Sage Therapeutics, Inc. (NASDAQ:SAGE) to report earnings on August, 2. They expect $-1.87 EPS, up 0.53% or $0.01 from last year’s $-1.88 per share. After $-1.68 actual EPS reported by Sage Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 11.31% negative EPS growth.

Sage Therapeutics, Inc. (NASDAQ:SAGE) Institutional Positions Chart